GH Research Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • Tuesday
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive OfficerGlobeNewsWire • Tuesday
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's WhyZacks Investment Research • 05/13/24
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should KnowZacks Investment Research • 05/10/24
GH Research Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/03/24
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%Zacks Investment Research • 03/05/24
GH Research Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 02/29/24
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionGlobeNewsWire • 01/18/24
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 01/16/24
GH Research Reports Third Quarter Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant DepressionGlobeNewsWire • 09/29/23
GH Research Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/23/23
GH Research Reports First Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/11/23
GH Research Reports Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/02/23
GH Research Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/10/22
Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?Zacks Investment Research • 09/14/22